<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02169921</url>
  </required_header>
  <id_info>
    <org_study_id>CVJ-12-02-01</org_study_id>
    <nct_id>NCT02169921</nct_id>
  </id_info>
  <brief_title>TurboHawk™ Japan Trial in Patients With PAD</brief_title>
  <official_title>Determination of Safety and Effectiveness of the TurboHawk and the SpiderFX for the Treatment of Peripheral Arterial Disease in the Superficial Femoral and/or the Popliteal Arteries in Japan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Endovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Endovascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and effectiveness of the TurboHawk for
      the treatment of peripheral arterial disease (PAD) in the superficial femoral and/or the
      popliteal arteries with the Japanese population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Patency Rate</measure>
    <time_frame>180 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical procedural success</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preservation of the number of run-off vessels determined by angiography</measure>
    <time_frame>intra operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event free survival</measure>
    <time_frame>30 Days , 180 Days and One Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amputation Rate</measure>
    <time_frame>30 Days , 180 Days and One Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Rutherford Clinical Category</measure>
    <time_frame>30 Days , 180 Days and One Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Ankle-Brachial Index</measure>
    <time_frame>30 Days , 180 Days and One Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically driven target lesion revascularisation</measure>
    <time_frame>30 Days , 180 Days and One Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically driven target vessel revascularisation</measure>
    <time_frame>30 Days , 180 Days and One Year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>TurboHawk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This study is designed as a single arm study. For angioplasty, the Atherectomy Catheter, TurboHawk is used in this arm. Spider FX, the Distal Embolus Protection Device, can concomitantly be used with TurboHawk</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Atherectomy Catheter</intervention_name>
    <description>Atherectomy Catheter, TurboHawk, is used for Angioplasty. Spider FX can concomitantly be used with TurboHawk.
TurboHawkTM LS-C, TurboHawk LX-C, TurboHawk SS-CL and TurboHawk SX-C are paticipated in this arm.</description>
    <arm_group_label>TurboHawk</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provides written informed consent

          -  Willing to comply with follow-up evaluations at specified times

          -  Has a Rutherford Clinical Category Score of 2-4

          -  Disease located within the femoropopliteal artery

          -  Has evidence of ≥ 50% stenosis or occlusion in the superficial femoral and/or
             popliteal, confirmed by angiography

          -  Each discrete target lesion's length is ≥4cm and ≤ 15 cm

          -  Reference vessel diameter is ≥ 3.5 mm and ≤ 7.0 mm

        Exclusion Criteria:

          -  Previously implanted stent(s) or stent graft(s) in target leg

          -  Life expectancy less than 12 months

          -  Has any planned surgical or endovascular intervention of target vessel 30 days before
             or after index procedure

          -  Has in-stent restenosis of the target lesion

          -  Has an aneurysmal target vessel

          -  Has perforation, dissection or other injury of the access or target vessel requiring
             additional stenting or surgical intervention prior to enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takao Ohki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jikei University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hiroshi Ando, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kasukabe Chuo General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kasukabe Chuo General Hospital</name>
      <address>
        <city>Kasukabe</city>
        <state>Saitama</state>
        <zip>344-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jikei University School of Medicine</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>105-8471</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2014</study_first_posted>
  <last_update_submitted>July 28, 2016</last_update_submitted>
  <last_update_submitted_qc>July 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

